NCT06824818

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 155 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: Male
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Conditions

• Elderly
• Prostate Cancer

Interventions

Type	Name	Description
BEHAVIORAL	LHRH Agonist Therapy Discontinuation	The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.

Timeline

• Start date: 2026-06-01
• Primary completion: 2026-12-01
• Completion: 2027-06-01
• First posted: 2025-02-13
• Last updated: 2025-10-01

Locations

2 sites across 1 country: United States